Continuing Education Activity

Gastrinomas are neuroendocrine tumors characterized by the secretion of gastrin with resultant excessive gastric acid production, causing severe peptic ulcer disease and diarrhea, a combination referred to as the Zollinger-Ellison syndrome (ZES). Gastrinomas are the most common functional and malignant pancreatic endocrine tumors. They are commonly diagnosed between the ages of 20 and 50 and have a slightly higher incidence in men. Unfortunately, at least 60 percent of gastrinoma cases have already metastasized by the time of diagnosis, hastening death. Improving the interprofessional team's knowledge regarding when to consider gastrinomas on differential diagnosis as well as how to promptly evaluate patients for this condition, will allow for earlier management and improved outcomes. This activity reviews the evaluation and treatment of patients with gastrinomas and the importance of ruling out multiple endocrine neoplasias. This activity highlights the role of the interprofessional team in caring for affected patients.

Objectives:

• Identify the etiology of gastrinomas.
• Review the physical presentation of a patient with gastrinoma.
• Describe the management options available for gastrinomas.
• Outline interprofessional team strategies for improving care coordination and communication to advance treatment and improve outcomes for patients with gastrinomas.

Introduction

Gastrinomas are neuroendocrine tumors characterized by the secretion of gastrin with resultant excessive gastric acid production, causing severe peptic ulcer disease and diarrhea, a combination referred to as the Zollinger-Ellison syndrome (ZES).[1][2][3]

Etiology

These tumors, along with other pancreatic endocrine tumors, appear to originate from endodermal pluripotent cells. Gastrinomas can be either sporadic (75% to 80%) or associated with multiple endocrine neoplasia type 1 (MEN-1) syndrome, an autosomal dominant inherited disorder (20% to 30%). MEN1 results from germline mutations in the tumor suppressor MEN1 gene located on chromosome 11q13. Researchers have proposed that the tumors arise in susceptible patients as a result of multiple independent second-hit mutations in the MEN1 gene.[4][5]

Epidemiology

The worldwide incidence of gastrinomas is about 0.5 to 3 cases/million per year. With improved techniques for tumor detection, the annual incidence has increased.  About 80% to 90% of these tumors arise in the so-called “gastrinoma triangle,” an anatomical area in the abdomen with boundaries formed superiorly by the confluence of the cystic and common bile ducts, inferiorly by the second and third portions of the duodenum, and medially by the neck of the pancreas. Gastrinomas can also rarely occur in the stomach, peri-pancreatic lymph nodes, liver, bile duct, ovary, or heart or be associated with small cell lung cancer. Duodenal gastrinomas are usually less than 1 cm, multiple, occur predominantly in the first part of the duodenum, and comprise approximately 50% to 88% of gastrinomas associated with sporadic ZES and 70% to 100% of gastrinomas associated with MEN 1. Pancreatic gastrinomas are larger than their duodenal counterparts, may occur in any portion of the pancreas, and comprise 25% of these tumors. Gastrinomas are also the most common functional and malignant pancreatic endocrine tumors. They are commonly diagnosed between the ages of 20 and 50 and have a slightly higher incidence in men. In patients with MEN1, gastrinomas present at an earlier age, commonly between the ages of 10 and 30 years. Gastrinomas are slow-growing tumors, but about 60% are malignant and have metastasized at the time of diagnosis. 

Pathophysiology

The gastrinoma tumor cells secrete excessive amounts of gastrin, which leads to hyperplasia of the fundic parietal cells and increases basal gastric acid output. The excessive gastric acid output breaches the mucosal defenses of the gastric as well as the duodenal wall, causes ulceration, and inactivates pancreatic digestive enzymes with resultant fat malabsorption and diarrhea. The inhibition of the absorption of sodium and water by the small intestine results in a secretory component of diarrhea.[6][7]

Histologically, a well-differentiated neuroendocrine tumor (NET) has a typical organoid arrangement of cells with nesting, trabecular, or gyriform patterns. The tumor cells are round with regular bland nuclei and produce large amounts of secretory granules with diffuse immunoexpression of neuroendocrine markers. In contrast, the poorly differentiated NET has atypical, sheet-like, diffuse, and irregular nuclei, less cytoplasmic secretory granules, and limited biomarker immunoexpression. An essential feature for the diagnosis of neuroendocrine tumors is immunostaining for chromogranin A and synaptophysin. Gastrin immunostaining can help to differentiate from other neuroendocrine tumors. Gastrinomas express a high density of somatostatin receptors, thus making somatostatin scintigraphy an effective localizing tool.

The WHO (2010) classified all neuroendocrine tumors, including gastrinomas, into three grades based on the mitotic rate, or Ki-67 index: (1) Low-grade, well-differentiated endocrine tumors with benign or uncertain behavior at the time of diagnosis with a mitotic rate of less than 2 and Ki-67 index of less than 3% (10% to 30%); (2) well-differentiated endocrine carcinomas with low-grade malignant behavior with a mitotic rate of 2 to 20 and Ki-67 index of 3% to 20%  (50% to 80%), and (3) High grade, poorly differentiated endocrine carcinomas with high-grade malignant behavior with a mitotic rate of greater than 20 and Ki-67 index of greater than 20% (1% to 3%).

History and Physical

The most common clinical manifestations include abdominal pain and chronic diarrhea. Other manifestations may include dyspepsia, gastroesophageal reflux, gastrointestinal bleeding, and weight loss. In patients with refractory/recurrent peptic ulcers (especially multiple and duodenal) and diarrhea, a diagnosis of gastrinoma must merit consideration. It is important to remember that ZES is the underlying cause in only about 0.1% to 1% of patients with peptic ulcer disease, so widespread screening is not recommended. Characteristically, diarrhea with ZES improves with the administration of proton pump inhibitors (PPIs).

Evaluation

The clinician can confirm the diagnosis through an elevated fasting serum gastrin concentration associated with increased basal gastric acid secretion and or low gastric PH. A normal fasting serum gastrin level excludes ZES. Hypergastrinemia also can be seen in patients with PPI therapy, hypercalcemia, atrophic gastritis, or gastric outlet obstruction; therefore, analysis of gastric acid secretion is useful. The majority of patients with gastrinomas have elevations in gastrin less than 10-fold above the upper limit of normal and may need confirmatory testing. A secretion stimulation test can help to differentiate from other causes of gastrinomas, but access to secretin is limited.

Chromogranin A is a non-specific serum biomarker of neuroendocrine tumors that correlates with tumor volume and may provide prognostic information and be useful for follow-up. Chromogranin A should be measured when fasting, and exercise should be avoided before testing. Multiphasic CT, MRI, nuclear medicine imaging: somatostatin receptor scintigraphy with SPECT/CT, gallium-somatostatin analog PET-CT imaging are non-invasive imaging modalities that can localize the tumor and help to evaluate the extent of metastatic spread. The presence of enlarged peripancreatic lymph nodes or liver metastases suggests malignancy. CT is relatively insensitive for small liver lesions, for which MRI is better. Endoscopy with endoscopic ultrasound is useful for small tumors that may be missed and have the added benefit of obtaining fine needle aspiration for histology. Due to low proliferative activity, the FDG-PET scan is not useful. In some patients, tumor localization can only be achieved during laparotomy by direct palpation by the surgeon or intra-operative ultrasound.[8][9][10]

All patients with ZES will require evaluation for MEN 1 syndrome by history (hypercalcemia, nephrolithiasis, pituitary tumors), including family history and biochemical assessment, including serum ionized calcium, parathyroid hormone levels, and prolactin. Patients can also have non-endocrine findings, including angiofibromas and collagenomas.[11][12][13][14][15]

Treatment / Management

The goal of medical management is to treat symptoms and prevent complications from peptic ulcer disease. The preferred medical therapy is the use of high doses of proton pump inhibitors. PPIs are preferable to H2 receptor blockers due to their higher potency and longer duration of action.

 Surgery is the only curative treatment for gastrinomas. All patients with sporadic gastrinoma in the absence of unresectable metastatic disease should receive a referral for surgery. In contrast, medical therapy is the current standard of care for most patients with MEN1-associated ZES due to the multiplicity of tumors, extra-pancreatic location, co-existent metastatic disease, and low chance of surgical cure. Surgical resection is recommended for MEN 1 associated gastrinomas greater than 2 cm.  

Metastases and the extent of metastatic spread are the most important determinant of mortality. The goal of surgery is to resect the primary tumor for a potential cure and reduce the risk of distant metastatic disease and improve survival. For a non-metastatic gastrinoma situated in the pancreas, surgical excision/enucleation is often effective. Duodenal gastrinomas are often multiple and often require duodenectomy. Regional lymph nodes should undergo systematic sampling. Patients undergoing surgery should receive PPIs. Patients are followed yearly with fasting serum gastrin and chromogranin A levels and imaging as needed after resection.

Conservative treatment with PPIs is the recommendation for patients who are unsuitable for surgery or patients with widespread metastasis.

Current treatment modalities for patients with metastatic disease have limited efficacy. Chemotherapy is an option for patients with widespread metastasis. The first-line treatment is combined therapy with streptozotocin and 5-fluorouracil or doxorubicin. However, these treatments have been shown to result in limited responses and considerable toxicity. Hormonal therapy with octreotide or lanreotide, which are human somatostatin analogs, is known to decrease gastric acid secretion but is not known to show any anti-tumor activity. In pancreatic neuroendocrine tumors, targeted therapies like antiangiogenic strategies, multi-kinase, or mTOR inhibition, which specifically inhibit growth factor receptors and their related signaling pathways, are promising new approaches and have provided clear clinical benefits in a few phase III clinical trials, including delayed tumor progression but are pending large-scale use and further clinical trials. Other treatment modalities include hepatic artery embolization for liver metastasis and administration of human leukocyte interferon. Radiotherapy is not generally recommended.

Differential Diagnosis

• Achlorhydria

• Atrophic gastritis

• Gastric outlet obstruction

• Peptic ulcer disease

• Pernicious anemia

• Zollinger-Ellison syndrome

Prognosis

Patients who receive a complete tumorectomy can expect a greater than 90% 5- to 10-year survival rate. With incomplete tumor removal, this drops to a 43% chance of 5-year survival and only a 25% chance for ten years.[16]

Complications

Complications may include:

• The surgeon's inability to locate the tumor during surgery
• Failure to remove all of the cancerous tissue
• Intestinal bleeding or perforation from duodenal or gastric ulcers
• Weight loss and/or severe diarrhea
• Metastases

Deterrence and Patient Education

Patients need to understand that these tumors can have a high survival rate if caught early and that medication compliance is crucial to therapeutic success regarding complications from these tumors.

Pearls and Other Issues

Liver metastases and the extent of liver involvement are the most important prognostic factors for survival. The effect of lymph node metastasis on patient survival is controversial. 

Enhancing Healthcare Team Outcomes

The diagnosis and management of gastrinomas are complex and require an interprofessional team that includes a general surgeon, endocrinologist, radiologist, pathologist, internist, and oncologist. While the symptoms are manageable with PPIs, localized lesions can be cured with surgery. All patients with sporadic gastrinoma in the absence of unresectable metastatic disease should receive a referral for surgery. In contrast, medical therapy is the current standard of care for most patients with MEN1-associated ZES due to the number of tumors, extra-pancreatic location, co-existent metastatic disease, and low chance of surgical cure. The recommendation is for surgical resection for MEN 1-associated gastrinomas greater than 2 cm.  

The outcomes for patients with localized lesions that are excisable are good. Patients with metastatic disease have poor outcomes.[17][18]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Cho MS, Kasi A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 21, 2022. Zollinger-Ellison Syndrome. [PubMed: 30726029]

2.

Prosapio JG, Sankar P, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 6, 2023. Physiology, Gastrin. [PubMed: 30521243]

3.

Keller HR, Record JL, Lall NU. Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings. Ochsner J. 2018 Summer;18(2):170-175. [PMC free article: PMC6135292] [PubMed: 30258300]

4.

Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am. 2018 Sep;47(3):577-601. [PMC free article: PMC6092039] [PubMed: 30098717]

5.

Pieterman CRC, van Leeuwaarde RS, van den Broek MFM, van Nesselrooij BPM, Valk GD. Multiple Endocrine Neoplasia Type 1. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Dec 22, 2021. [PubMed: 29465925]

6.

Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018 Sep;18(9):837-860. [PMC free article: PMC6283410] [PubMed: 29973077]

7.

Rossi RE, Rausa E, Cavalcoli F, Conte D, Massironi S. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. Scand J Gastroenterol. 2018 Jun-Jul;53(7):835-842. [PubMed: 29726295]

8.

Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord. 2018 Jun;19(2):145-158. [PubMed: 29464446]

9.

Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4(4):167-185. [PMC free article: PMC5757869] [PubMed: 29326808]

10.

Fottner C, Ferrata M, Weber MM. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017 Dec;18(4):393-410. [PubMed: 29256148]

11.

Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Cremonini N, Davi MV, Funicelli L, Massironi S, Spada F, Toscano V, Versari A, Zini M, Falconi M, Oberg K. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Metab Immune Disord Drug Targets. 2018;18(5):419-449. [PubMed: 29237387]

12.

Fendrich V, Bartsch DK. Surgical Therapy of Sporadic Pancreatic Neuroendocrine Neoplasias G1/G2. Visc Med. 2017 Oct;33(5):344-350. [PMC free article: PMC5697504] [PubMed: 29177163]

13.

Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A., NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine. 2018 Apr;60(1):15-27. [PubMed: 29019150]

14.

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML., Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011. [PubMed: 22723327]

15.

Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab. 2004 Nov;89(11):5328-36. [PubMed: 15531478]

16.

Norton JA, Foster DS, Blumgart LH, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT. Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract. JAMA Surg. 2018 Mar 01;153(3):e175083. [PMC free article: PMC5885930] [PubMed: 29365025]

17.

Crown A, Kennecke H, Kozarek R, Lopez-Aguiar AG, Dillhoff M, Beal EW, Poultsides GA, Makris E, Idrees K, Smith PM, Nathan H, Beems M, Abbott D, Fisher AV, Fields RC, Davidson J, Maithel SK, Rocha FG. Gastric carcinoids: Does type of surgery or tumor affect survival? Am J Surg. 2019 May;217(5):937-942. [PubMed: 30686481]

18.

Giovinazzo F, Butturini G, Monsellato D, Malleo G, Marchegiani G, Bassi C. Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg. 2013 Mar;65(1):19-24. [PubMed: 23417896]

Disclosure: Shashank Cingam declares no relevant financial relationships with ineligible companies.

Disclosure: Mahesh Botejue declares no relevant financial relationships with ineligible companies.

Disclosure: Gilles Hoilat declares no relevant financial relationships with ineligible companies.

Disclosure: Harsha Karanchi declares no relevant financial relationships with ineligible companies.